Advertisement

Biochemistry (Moscow)

, Volume 76, Issue 11, pp 1242–1252 | Cite as

Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562

  • E. A. Lesovaya
  • A. Yu. Yemelyanov
  • K. I. Kirsanov
  • M. G. Yakubovskaya
  • I. V. Budunova
Article

Abstract

Glucocorticoids (GCs) are widely used in chemotherapy of hematological malignancies, particularly leukemia. Their effect is mediated by glucocorticoid receptor (GR), a well-known transcription factor. Besides their therapeutic impact, GCs may cause a number of side effects leading to various metabolic complications. The goal of immediate interest is testing glucocorticoid analogs capable of induction/enhancement of GR transrepression, but preventing GR dimerization and transactivation leading to side effects. In this work we have investigated effects of a promising new selective GR agonist, 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride (CpdA), on CEM and K562 leukemia cells. Both cell lines express functional GR. CpdA compared with the glucocorticoid fluocinolone acetonide (FA) exerted more prominent cytostatic and apoptotic effects on the cells. Both cell lines exhibited sensitivity to CpdA, demonstrating a good correlation with the effects of FA on cell growth and viability. In contrast to FA, CpdA did not induce GR transactivation evaluated by no obvious increase in expression of GR target (and dependent) gene FKBP51. At the same time, luciferase assay showed that CpdA efficiently activated transrepression of NF-ϰB and AP-1 factors. We also evaluated the effect of combined action of CpdA and the proteasome inhibitor Bortezomib. The latter induced a caspase-dependent apoptosis in both T-cell leukemia cell lines. By treatment of CEM cells with different CpdA/GC and Bortezomib doses, we have designed a protocol where CpdA shows potentiating effect on Bortezomib cytotoxic activity. Generally, the present work characterizes a novel non-steroid GR ligand, CpdA, as a promising compound for possible application in leukemia chemotherapy.

Key words

glucocorticoid receptor leukemia selective GR agonist 

Abbreviations

CpdA

2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride

DMSO

dimethyl sulfoxide

ER

endoplasmic reticulum

FA

fluocinolone acetonide

GAPDH

glyceraldehyde-3-phosphate dehydrogenase

GC

glucocorticoid

GR

glucocorticoid receptor

HDAC-1

histone deacetylase-1

PARP

poly(ADP-ribose) polymerase

PI

propidium iodide

SEGRA

selective GR agonist

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adcock, I. M. (2000) Pulm. Pharm. Ther., 13, 115–126.CrossRefGoogle Scholar
  2. 2.
    Chebotaev, D., Yemelyanov, A., and Budunova, I. (2007) Mol. Carcinog., 46, 732–740.PubMedCrossRefGoogle Scholar
  3. 3.
    Rehwinkel, H., and Schacke, H. (2006) Chem. Med. Chem., 1, 803–805.PubMedGoogle Scholar
  4. 4.
    Schacke, H., Berger, M., Rehwinkel, H., and Asadullah, K. (2007) Mol. Cell Endocrinol., 275, 109–117.PubMedCrossRefGoogle Scholar
  5. 5.
    Yemelyanov, A., Czwornog, J., Chebotaev, D., Karseladze, A., Kulevitch, E., Yang, X., and Budunova, I. (2007) Oncogene, 26, 1885–1896.PubMedCrossRefGoogle Scholar
  6. 6.
    Louw, A., and Swart, P. (1999) Endocrinology, 140, 2044–2053.PubMedCrossRefGoogle Scholar
  7. 7.
    Yemelyanov, A., Czwornog, J., Gera, L., Joshi, S., Chatterton, R. T., Jr., and Budunova, I. (2008) Cancer Res., 68, 4763–4773.PubMedCrossRefGoogle Scholar
  8. 8.
    De Bosscher, K., Vanden Berghe, W., Beck, I. M. E., van Molle, W., Hennuyer, N., Hapgood, J., Libert, C., Staels, B., Louw, A., and Haegeman, G. (2005) Proc. Natl. Acad. Sci. USA, 102, 15827–15832.PubMedCrossRefGoogle Scholar
  9. 9.
    Dewint, P., Gossye, V., de Bosscher, K., Vanden Berghe, W., Muller-Ladner, U., Vander Cruyssen, B., Haegeman, G., and Elewaut, D. (2008) J. Immunol., 180, 2608–2615.PubMedGoogle Scholar
  10. 10.
    Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D. L., Elliott, P. J., Pien, C. S., Guerciolini, R., Anderson, J. K., Depcik-Smith, N. D., Bhagat, R., Lehman, M. J., Novick, S. C., O’Connor, O. A., and Soignet, S. L. (2002) J. Clin. Oncol., 20, 4420–4427.PubMedCrossRefGoogle Scholar
  11. 11.
    McConkey, D. J., and Zhu, K. (2008) Drug Resist., 11, 164–179.CrossRefGoogle Scholar
  12. 12.
    Romaguera, J. E., Fayad, L. E., McLaughlin, P., Pro, B., Rodriguez, A., Wang, M., Weaver, P., Hartig, K., Kwak, L. W., Feldman, T., Smith, J., Ford, P., Goldberg, S., Pecora, A., and Goy, A. (2010) Br. J. Haematol., 151, 47–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Messinger, Y., Gaynon, P., Raetz, E., Hutchinson, R., Dubois, S., Glade-Bender, J., Sposto, R., van der Giessen, J., Eckroth, E., and Bostrom, B. C. (2010) Pediatr. Blood Cancer, 55, 254–259.PubMedCrossRefGoogle Scholar
  14. 14.
    Elliott, P. J., Zollner, T. M., and Boehncke, W.-H. (2003) J. Mol. Med., 81, 235–245.PubMedGoogle Scholar
  15. 15.
    Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., and Grant, S. (2003) Blood, 102, 3765–3774.PubMedCrossRefGoogle Scholar
  16. 16.
    Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. (2001) Cancer Res., 61, 3535–3540.PubMedGoogle Scholar
  17. 17.
    Kraus, M., Malenke, E., Gogel, J., Muller, H., Ruckrich, T., Overkleeft, H., Ovaa, H., Koscielniak, E., Hartmann, J. T., and Driessen, C. (2008) Mol. Cancer Ther., 7, 1940–1948.PubMedCrossRefGoogle Scholar
  18. 18.
    Horton, T. M., Gannavarapu, A., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., and Berg, S. L. (2006) Cancer Chemother. Pharmacol., 58, 13–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenberg, I. M. (1996) Protein Analysis and Purification Benchtop Techniques, Birkhauser, Boston, MA.Google Scholar
  20. 20.
    Verma, R. P. (2006) Anticancer Agents Med. Chem., 6, 489–499.PubMedCrossRefGoogle Scholar
  21. 21.
    Miller, A. L., Garza, A. S., Johnson, B. H., and Thompson, E. B. (2007) Cancer Cell. Int., 7, 3.PubMedCrossRefGoogle Scholar
  22. 22.
    Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A., and McCarthy, R. E. (1965) Cancer, 18, 522–529.PubMedCrossRefGoogle Scholar
  23. 23.
    Norman, M. R., and Thompson, E. B. (1977) Cancer Res., 37, 3785–3791.PubMedGoogle Scholar
  24. 24.
    Klein, E., Ben-Bassat, H., Neumann, H., Ralph, P., Zeuthen, J., Polliack, A., and Vanky, F. (1976) Int. J. Cancer, 18, 421–431.PubMedCrossRefGoogle Scholar
  25. 25.
    Mihailovic, T., Marx, M., Auer, A., van Lint, J., Schmid, M., Weber, C., and Seufferlein, T. (2004) Cancer Res., 64, 8939–8944.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Etten, R. (2007) J. Exp. Med., 204, 461–465.PubMedCrossRefGoogle Scholar
  27. 27.
    Tefferi, A., and Vardiman, J. W. (2007) Curr. Opin. Hematol., 14, 115–122.PubMedCrossRefGoogle Scholar
  28. 28.
    Chiaretti, S., and Foa, R. (2009) Haematologica, 94, 160–162.PubMedCrossRefGoogle Scholar
  29. 29.
    Agius, C., and Gidari, A. S. (1982) J. Lab. Clin. Med., 100, 178–185.PubMedGoogle Scholar
  30. 30.
    Schmidt, S., Irving, J. A., Minto, L., Matheson, E., Nicholson, L., Ploner, A., Parson, W., Kofler, A., Amort, M., Erdel, M., Hall, A., and Kofler, R. (2006) FASEB J., 20, 2600–2602.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramos, R. A., Meilandt, W. J., Wang, E. C., and Firestone, G. L. (1999) FASEB J., 13, 169–180.PubMedGoogle Scholar
  32. 32.
    Ruiz, M., Lind, U., Gafvels, M., Eggertsen, G., Carlstedt-Duke, J., Nilsson, L., Holtmann, M., Stierna, P., Wikstrom, A. C., and Werner, S. (2001) Clin. Endocrinol. (Oxf.), 55, 363–371.CrossRefGoogle Scholar
  33. 33.
    Beesley, A. H., Weller, R. E., Senanayake, S., Welch, M., and Kees, U. R. (2009) Leuk. Res., 33, 321–325.PubMedCrossRefGoogle Scholar
  34. 34.
    Irving, J. A., Minto, L., Bailey, S., and Hall, A. G. (2005) Cancer Res., 65, 9712–9718.PubMedCrossRefGoogle Scholar
  35. 35.
    Kester, H. A., van der Leede, B. M., van der Saag, P. T., and van der Burg, B. (1997) J. Biol. Chem., 272, 16637–16643.PubMedCrossRefGoogle Scholar
  36. 36.
    Wallace, A. D., and Cidlowski, J. A. (2001) J. Biol. Chem., 276, 42714–42721.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen, D. W., Lynch, J. T., Demonacos, C., Krstic-Demonacos, M., and Schwartz, J. M. (2010) Pharmaco-genomics, 11, 1545–1560.Google Scholar
  38. 38.
    Gossye, V., Elewaut, D., van Beneden, K., Dewint, P., Haegeman, G., and de Bosscher, K. (2010) Ann. Rheum. Dis., 69, 291–296.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee, W., Mitchell, P., and Tjian, R. (1987) Cell, 49, 741–752.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen, L., Glover, J. N. M., Hogan, P. G., Rao, A., and Harrison, S. C. (1998) Nature, 392, 42–48.PubMedCrossRefGoogle Scholar
  41. 41.
    Miller, A. L., Webb, M. S., Copik, A. J., Wang, Y., Johnson, B. H., Kumar, R., and Thompson, E. B. (2005) Mol. Endocrinol., 19, 1569–1583.PubMedCrossRefGoogle Scholar
  42. 42.
    Gossye, V., Elewaut, D., Bougarne, N., Bracke, D., van Calenbergh, S., Haegeman, G., and de Bosscher, K. (2009) Arthritis Rheum., 60, 3241–3250.PubMedCrossRefGoogle Scholar
  43. 43.
    Hartmann, B. L., Geley, S., and Kofler, R. (1999) Wien Klin. Wochenschr., 111, 360–367.PubMedGoogle Scholar
  44. 44.
    Tripathi, P., and Aggarwal, A. (2006) Curr. Sci., 90, 519–531.Google Scholar
  45. 45.
    Hermoso, M. A., and Cidlowski, J. A. (2003) IUBMB Life, 55, 497–504.PubMedCrossRefGoogle Scholar
  46. 46.
    Hernandez-Espinosa, D., Minano, A., Ordonez, A., Mota, R., Martinez-Martinez, I., Vicente, V., and Corral, J. (2009) J. Thromb. Haemost., 7, 1128–1133.PubMedCrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2011

Authors and Affiliations

  • E. A. Lesovaya
    • 1
  • A. Yu. Yemelyanov
    • 2
  • K. I. Kirsanov
    • 1
  • M. G. Yakubovskaya
    • 1
  • I. V. Budunova
    • 2
  1. 1.Institute of Carcinogenesis, Blokhin Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia
  2. 2.Feinberg Medical School, Department of DermatologyNorthwestern UniversityChicagoUSA

Personalised recommendations